Currently, only PD-L1 expression has been shown clinical utility in HNSCC, as patients with a PD-L1 CPS ≥ 1 are more likely to respond to anti-PD-1 immunotherapy. Here, PDCD1 is linked to head and neck squamous cell carcinoma.